Q1 EPS Estimate for Bausch Health Cos Lowered by Analyst

Bausch Health Cos Inc. (NYSE:BHC) – Investment analysts at Zacks Research reduced their Q1 2027 EPS estimates for Bausch Health Cos in a research report issued to clients and investors on Friday, July 24th. Zacks Research analyst Team now anticipates that the company will post earnings per share of $0.80 for the quarter, down from their prior forecast of $0.82. The consensus estimate for Bausch Health Cos’ current full-year earnings is $4.05 per share. Zacks Research also issued estimates for Bausch Health Cos’ FY2027 earnings at $3.62 EPS, Q1 2028 earnings at $0.58 EPS and FY2028 earnings at $3.08 EPS.

Bausch Health Cos (NYSE:BHC) last announced its earnings results on Wednesday, April 29th. The company reported $0.78 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.81 by ($0.03). The company had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.37 billion. Bausch Health Cos had a negative net margin of 11.47% and a negative return on equity of 2,922.77%.

A number of other research firms also recently weighed in on BHC. Weiss Ratings downgraded Bausch Health Cos from a “sell (d)” rating to a “sell (d-)” rating in a research report on Monday, May 4th. Royal Bank Of Canada decreased their price objective on Bausch Health Cos from $10.00 to $9.00 and set a “sector perform” rating on the stock in a report on Monday, April 27th. Finally, Jefferies Financial Group upgraded Bausch Health Cos to a “hold” rating in a research report on Wednesday, July 22nd. Five research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Bausch Health Cos currently has a consensus rating of “Reduce” and an average target price of $8.00.

Bausch Health Cos Stock Performance

NYSE BHC opened at $4.49 on Monday. Bausch Health Cos has a 52-week low of $4.33 and a 52-week high of $8.69. The company has a debt-to-equity ratio of 54.68, a quick ratio of 0.97 and a current ratio of 1.32. The company has a market capitalization of $1.68 billion, a P/E ratio of -1.38 and a beta of 0.42. The company has a fifty day moving average of $4.98 and a 200-day moving average of $5.52.

Institutional Investors Weigh In On Bausch Health Cos

Several hedge funds have recently added to or reduced their stakes in BHC. Hillsdale Investment Management Inc. bought a new position in Bausch Health Cos in the 4th quarter worth about $3,651,000. Ritholtz Wealth Management grew its position in Bausch Health Cos by 178.8% during the 1st quarter. Ritholtz Wealth Management now owns 222,459 shares of the company’s stock valued at $1,201,000 after purchasing an additional 142,663 shares during the last quarter. Private Management Group Inc. increased its stake in Bausch Health Cos by 16.7% during the 4th quarter. Private Management Group Inc. now owns 1,892,895 shares of the company’s stock valued at $13,156,000 after purchasing an additional 271,170 shares in the last quarter. Banco BTG Pactual S.A. bought a new stake in Bausch Health Cos during the 4th quarter valued at about $1,186,000. Finally, Norges Bank purchased a new position in Bausch Health Cos in the fourth quarter worth about $25,592,000. 78.65% of the stock is owned by institutional investors.

Insider Buying and Selling at Bausch Health Cos

In other news, Director Frank D. Lee sold 24,456 shares of the business’s stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $5.43, for a total value of $132,796.08. Following the sale, the director directly owned 49,339 shares of the company’s stock, valued at $267,910.77. The trade was a 33.14% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 20.67% of the company’s stock.

Bausch Health Cos Company Profile

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.